Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Bipolar Big Three: LAIs, Atypical Antipsychotics And Symptom Specific Drugs

Room For Growth Beyond Generics

Executive Summary

Despite the highly genericized nature of the bipolar disorder market, firms have innovated with long-acting injectables, improved atypical antipsychotics and drugs targeting specific symptoms.

You may also be interested in...



New Products Shake Up Overlooked Bipolar Disorder Market

The highly genericized bipolar disorder market is set for change as both new long-acting injectable formulations of older products and novel therapies reach the market, while firms like NRx and BioXcel target major unmet needs in a disease that needs more R&D.

Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability

Sales for the migraine product were lower in Q4 than consensus forecasts projected, but reduced costs have pushed yearly earnings beyond expectations.

Alkermes Expects Gradual Ramp-Up For Lybalvi Launch

Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel